[company_age]unknown[/company_age][employees]2-10 employees[/employees][description]Tixupharma is an innovative drug and medical device company based in Milan, Italy. Founded in 2013 as an academic spin-out, the company has consolidated its position in the regenerative medicine space by leveraging emerging strategies in traumatic and age-related diseases. Tixupharma's mission is to develop first-in-class therapeutics to treat immunoaging and traumatic diseases by leveraging metabolic driving-forces. The company's multidisciplinary team combines expertise in drug discovery, clinical trials, regulatory and IP, industrial operations, and business development. Tixupharma's core therapeutic areas are Women's Genitourinary disorders ('Ubigel') and Musculoskeletal ('Epitrol') disorders. The company also has assets in vascular-neurotrophic utility in Ophthalmology ('Troflo') and early-stage cerebrovascular therapy ('Relinca').[/description][ps]Drug and medical device development[/ps]